Bulletin du Cancer
Volume 91, special issue 2, Numéro spécial, Mai 2004
Editorial
Inhibiteurs de la cyclo‐oxygénase 2 et cancer
(p.59-60)
Thierry André, Jean‐Charles Soria
Synthèse
Cyclooxygenase 2 and carcinogenesis
(p.61-76)
Sylvie Rodrigues, Erik Bruyneel, Christelle M. Rodrigue, Emami Shahin, Christian Gespach
Cyclooxygenase 2 inhibitors and cancer chemoprevention
(p.77-84)
Amine Masmoudi, Thierry Le Chevalier, Laure Sabatier, Jean‐Charles Soria
Cyclooxygenase 2 inhibitors and adenomatous polyposis coli
(p.85-8)
Christian Florent, Nathalie Meary
Cyclooxygenase 2 inhibitors and colorectal cancer
(p.89-98)
Marianne Bernardeau‐Mozer, Stanislas Chaussade
Cyclooxygenase 2 and breast cancer
(p.99-108)
Jean‐Paul Guastalla, Thomas Bachelot, Isabelle Ray‐Coquard
Cyclooxygenase 2 inhibitors and lung carcinoma
(p.109-12)
Jean‐Philippe Spano, Kader Chouahnia, Jean‐François Morère
Cyclooxygenase 2 inhibitors and urologic and gynaecologic cancers
(p.113-6)
Pascal Eschwege
Safety of the selective inhibitors the inducible cyclooxygenase‐2 taken for long period
(p.117-24)
Dominique Lamarque
Analgesic effects of cyclooxygenase 2 inhibitors
(p.125-31)
Christian Jayr